

Table SI. First-line chemotherapy by hospital scale and type.

First-line systemic therapy	High volume (n≥50), n (%) (n=509)	Low volume (n<50), n (%) (n=337)	Government designated cancer hospital, n (%) (n=218)	Prefectural designated cooperative cancer hospital, n (%) (n=316)	General hospital, n (%) (n=312)
Gemcitabine monotherapy	184 (36.1)	118 (35.0)	94 (43.1)	102 (32.2)	106 (34.0)
S-1 monotherapy	115 (22.6)	82 (24.3)	39 (17.9)	76 (24.1)	82 (26.3)
Gemcitabine plus S-1	30 (5.9)	36 (10.7)	0 (0.0)	25 (7.9)	41 (13.1)
Gemcitabine plus nab-paclitaxel	156 (30.6)	73 (21.7)	77 (35.3)	94 (29.7)	58 (18.6)
FOLFIRINOX	24 (4.7)	28 (8.3)	8 (3.7)	19 (6.0)	25 (8.0)

FOLFIRINOX, fluorouracil, folic acid, oxaliplatin and irinotecan; nab, nanoparticle albumin-bounded; S-1, tegafur/gimeracil/oteracil.